EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P2)

被引：0
|
作者：
Gratacos-Masmitja, J. [1 ]
Turkiewicz, A. [2 ]
Dokoupilova, E. [3 ,4 ]
Gellett, A. M. [5 ]
Sprabery, T. [5 ]
Geneus, V. J. [5 ]
Constantin, A. [6 ]
机构：
[1] Univ Hosp Parc Tauli Sabadell, Barcelona, Spain
[2] Rheumatol Associates PC, Birmingham, AL USA
[3] Med Plus Sro, Uherske Hradiste, Czech Republic
[4] Univ Vet & Pharmaceut Sci, Dept Pharmaceut, Fac Pharm, Brno, Czech Republic
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Hosp Pierre Paul Riquet, Toulouse, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.1482
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
SAT0411
引用
收藏
页码：1154 / 1154
页数：1
相关论文
共 50 条
  • [1] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
    Orbai, Ana-Maria
    Gratacos, Jordi
    Turkiewicz, Anthony
    Hall, Stephen
    Dokoupilova, Eva
    Combe, Bernard
    Nash, Peter
    Gallo, Gaia
    Bertram, Clinton C.
    Gellett, Amanda M.
    Sprabery, Aubrey Trevelin
    Birt, Julie
    Macpherson, Lisa
    Geneus, Vladimir J.
    Constantin, Arnaud
    RHEUMATOLOGY AND THERAPY, 2021, 8 (01) : 199 - 217
  • [2] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3-Year Follow-Up (SPIRIT-P2)
    Ana-Maria Orbai
    Jordi Gratacós
    Anthony Turkiewicz
    Stephen Hall
    Eva Dokoupilova
    Bernard Combe
    Peter Nash
    Gaia Gallo
    Clinton C. Bertram
    Amanda M. Gellett
    Aubrey Trevelin Sprabery
    Julie Birt
    Lisa Macpherson
    Vladimir J. Geneus
    Arnaud Constantin
    Rheumatology and Therapy, 2021, 8 : 199 - 217
  • [3] Efficacy and Safety of Ixekizumab in Patients with Psoriatic Arthritis and Inadequate Response to TNF Inhibitors: 3 Year Results from a Phase 3 Study
    Gratacos, Jordi
    Turkiewicz, Anthony
    Dokoupilova, Eva
    Gellett, Amanda
    Sprabery, Aubrey
    Geneus, Vladimir
    Constantin, Arnaud
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [4] Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2
    Genovese, Mark C.
    Combe, Benard
    Kremer, Joel M.
    Tsai, Tsen-Fang
    Behrens, Frank
    Adams, David H.
    Lee, Chin
    Kerr, Lisa
    Nash, Peter
    RHEUMATOLOGY, 2018, 57 (11) : 2001 - 2011
  • [5] IMPROVED PAIN AND FATIGUE WITH IXEKIZUMAB TREATMENT IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PREVIOUS INADEQUATE RESPONSE TO TNF INHIBITORS: THREE YEAR FOLLOW-UP FROM A PHASE 3 STUDY (SPIRIT-P2)
    Orbai, A. M.
    De Vlam, K.
    Nash, P.
    Birt, J.
    Gallo, G.
    Stenger, K.
    Geneus, V.
    Combe, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 771 - 771
  • [6] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 23 - 24
  • [7] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: Three Year Results from a Phase 3 Study (SPIRIT-P1)
    Chandran, Vinod
    Fleischmann, Roy
    Lespessailles, Eric
    Helliwell, Philip
    Benichou, Olivier
    Erickson, Janelle
    Shuler, Catherine
    JOURNAL OF RHEUMATOLOGY, 2019, 46 (07) : 845 - 845
  • [8] EFFICACY AND SAFETY OF IXEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: THREE YEAR RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Chandran, V.
    Fleischmann, R.
    Lespessailles, E.
    Helliwell, P. S.
    Benichou, O.
    Erickson, J.
    Shuler, C.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 385 - 385
  • [9] INTEGRATED EFFICACY AND SAFETY RESULTS FROM SPIRIT-P1 AND SPIRIT-P2, TWO PHASE 3 TRIALS OF IXEKIZUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS
    Combe, B.
    Nash, P.
    Adams, D.
    Kerr, L.
    Moriarty, S.
    Benichou, O.
    INTERNAL MEDICINE JOURNAL, 2018, 48 : 41 - 41
  • [10] Integrated Efficacy and Safety Results From SPIRIT-P1 and SPIRIT-P2, Two Phase 3 Trials of Ixekizumab for the Treatment of Psoriatic Arthritis
    Combe, Bernard
    Nash, Peter
    Adams, David
    Kerr, Lisa
    Moriarty, Susan
    Benichou, Olivier
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 17 - 18
12345